合同制药商龙沙预测2026年销售增长将放缓——wkzo.com
Contract drug manufacturer Lonza forecasts slower sales growth for 2026 - wkzo.com
生命科学资讯
生物技术与制药领域的最新动态
龙沙集团预测核心CDMO业务至2026年销售额将增长11-12% - MSN
Lonza forecasts 2026 sales growth of 11-12% for core CDMO business - MSN
龙沙集团销售额因新合约势头增长——《华尔街日报》
Lonza Sales Grow on New Contract Momentum - The Wall Street Journal
龙沙集团预测核心CDMO业务2026年销售额增长11-12%——全球银行与金融评论
Lonza forecasts 2026 sales growth of 11-12% for core CDMO business - Global Banking & Finance Review
龙沙集团2025财年实现强劲盈利增长，并顺利完成瓦卡维尔工厂整合 - TradingView
Lonza Delivers Strong Profitable Growth in Full-Year 2025 and Successfully Completes Vacaville Site Integration - TradingView
Thermo Fisher Scientific (TMO) 股价近期上涨后估值评估 - 雅虎财经
Thermo Fisher Scientific (TMO) Valuation Check After Recent Share Price Momentum - Yahoo Finance
诺和诺德业务发展主管在200场摩根大通会议中寻找下一个Metsera。
With 200 JPM meetings, Novo Nordisk BD head searches for the next Metsera
CMS选定礼来Trulicity和吉利德Biktarvy进入第三轮Medicare价格谈判。
CMS picks Lilly’s Trulicity, Gilead's Biktarvy for third round of Medicare negotiations
罗氏公布GLP-1/GIP双重受体激动剂二期研究积极结果 | 医药行业高管
Roche Reports Positive Phase II Study Results for Dual GLP-1/GIP Receptor Agonist | PharmExec - Pharmaceutical Executive
研发百强获奖者聚焦：深入解读赛默飞世尔科技2025年三项研发百强奖项——研发世界
R&D 100 Winner Spotlight: A closer look at Thermo Fisher Scientific's trio of R&D 100 wins in 2025 - R&D World
赛默飞世尔科技2025年第四季度财报前瞻：近期内部交易、对冲基金活动及其他动态——Quiver Quantitative
THERMO FISHER SCIENTIFIC Q4 2025 Earnings Preview: Recent $TMO Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
剖析10x Genomics：13位分析师分享观点 - Benzinga
Breaking Down 10x Genomics: 13 Analysts Share Their Views - Benzinga
胶囊技术拓展单细胞实验可能性 - GenomeWeb
Capsule Techs Expand Possibilities for Experiments on Single Cells - GenomeWeb
美国医保服务中心提议：医院采购美国制造药品可获得更多收益。
Hospitals could earn more for buying US-made drugs, CMS proposes
心脏病发作新解：神经系统紊乱或成新药靶点
Rethinking heart attacks as nervous system gone haywire sparks potential new drug targets
TD Cowen精选其“骨骼、机器人与无针注射”投资组合中的三大医疗科技潜力股。
TD Cowen picks top 3 medtech prospects across its ‘Bones, Bots, and No More Shots’ portfolio
卡迪夫高管离职，公司二期试验数据喜忧参半。
Cardiff execs depart as company drops mixed Phase 2 data
联合健康集团调整业务布局，预计2026年营收将下滑
UnitedHealth projects lower revenue in 2026 as it resets its business
前Cytodyn首席执行官面临监禁及数百万赔偿
Former Cytodyn CEO faces prison time, millions in restitution
2026年1月27日任命与晋升公告
Appointments and advancements for Jan. 27, 2026